Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
AMWL vs OPRX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
AMWL vs OPRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $129M | $124M |
| Revenue (TTM) | $182M | $109M |
| Net Income (TTM) | $-88M | $5M |
| Gross Margin | 38.7% | 67.3% |
| Operating Margin | -50.6% | 10.7% |
| Forward P/E | — | 7.0x |
| Total Debt | $5M | $5M |
| Cash & Equiv. | $182M | $23M |
AMWL vs OPRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| American Well Corpo… (AMWL) | 100 | 1.3 | -98.7% |
| OptimizeRx Corporat… (OPRX) | 100 | 31.8 | -68.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMWL vs OPRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMWL is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.47
- Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
- Beta 1.47, current ratio 3.37x
OPRX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
- 110.5% 10Y total return vs AMWL's -98.3%
- 18.8% revenue growth vs AMWL's -2.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.8% revenue growth vs AMWL's -2.0% | |
| Quality / Margins | 4.7% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 1.47 vs OPRX's 2.28, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +14.3% vs OPRX's -30.1% | |
| Efficiency (ROA) | 3.0% ROA vs AMWL's -25.1%, ROIC 7.1% vs -95.1% |
AMWL vs OPRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMWL vs OPRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
OPRX leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMWL is the larger business by revenue, generating $182M annually — 1.7x OPRX's $109M. OPRX is the more profitable business, keeping 4.7% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, OPRX holds the edge at -0.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $182M | $109M |
| EBITDAEarnings before interest/tax | -$59M | $16M |
| Net IncomeAfter-tax profit | -$88M | $5M |
| Free Cash FlowCash after capex | -$42M | $12M |
| Gross MarginGross profit ÷ Revenue | +38.7% | +67.3% |
| Operating MarginEBIT ÷ Revenue | -50.6% | +10.7% |
| Net MarginNet income ÷ Revenue | -48.2% | +4.7% |
| FCF MarginFCF ÷ Revenue | -22.9% | +10.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -0.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +44.5% | — |
Valuation Metrics
AMWL leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $129M | $124M |
| Enterprise ValueMkt cap + debt − cash | -$48M | $105M |
| Trailing P/EPrice ÷ TTM EPS | -1.30x | 24.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.04x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 6.55x |
| Price / SalesMarket cap ÷ Revenue | 0.52x | 1.13x |
| Price / BookPrice ÷ Book value/share | 0.50x | 0.98x |
| Price / FCFMarket cap ÷ FCF | — | 6.62x |
Profitability & Efficiency
OPRX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
OPRX delivers a 4.2% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-33 for AMWL. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to OPRX's 0.04x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs AMWL's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -33.5% | +4.2% |
| ROA (TTM)Return on assets | -25.1% | +3.0% |
| ROICReturn on invested capital | -95.1% | +7.1% |
| ROCEReturn on capital employed | -36.6% | +7.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.02x | 0.04x |
| Net DebtTotal debt minus cash | -$178M | -$19M |
| Cash & Equiv.Liquid assets | $182M | $23M |
| Total DebtShort + long-term debt | $5M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -239.18x | 1.26x |
Total Returns (Dividends Reinvested)
OPRX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OPRX five years ago would be worth $1,266 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs OPRX's -30.1%. The 3-year compound annual growth rate (CAGR) favors OPRX at -23.0% vs AMWL's -42.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +59.8% | -46.6% |
| 1-Year ReturnPast 12 months | +14.3% | -30.1% |
| 3-Year ReturnCumulative with dividends | -80.7% | -54.4% |
| 5-Year ReturnCumulative with dividends | -97.2% | -87.3% |
| 10-Year ReturnCumulative with dividends | -98.3% | +110.5% |
| CAGR (3Y)Annualised 3-year return | -42.2% | -23.0% |
Risk & Volatility
AMWL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMWL is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs OPRX's 29.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 2.28x |
| 52-Week HighHighest price in past year | $9.15 | $22.25 |
| 52-Week LowLowest price in past year | $3.71 | $5.54 |
| % of 52W HighCurrent price vs 52-week peak | +84.7% | +29.8% |
| RSI (14)Momentum oscillator 0–100 | 67.1 | 46.9 |
| Avg Volume (50D)Average daily shares traded | 59K | 476K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $17.00 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
OPRX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMWL leads in 2 (Valuation Metrics, Risk & Volatility).
AMWL vs OPRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AMWL or OPRX a better buy right now?
For growth investors, OptimizeRx Corporation (OPRX) is the stronger pick with 18.
8% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMWL or OPRX?
Over the past 5 years, OptimizeRx Corporation (OPRX) delivered a total return of -87.
3%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMWL or OPRX?
By beta (market sensitivity over 5 years), American Well Corporation (AMWL) is the lower-risk stock at 1.
47β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 55% more volatile than AMWL relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 4% for OptimizeRx Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AMWL or OPRX?
By revenue growth (latest reported year), OptimizeRx Corporation (OPRX) is pulling ahead at 18.
8% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 57. 1% for American Well Corporation. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AMWL or OPRX?
OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.
7% net margin versus -38. 4% for American Well Corporation — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — OPRX leads at 67. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AMWL or OPRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AMWL or OPRX better for a retirement portfolio?
For long-horizon retirement investors, American Well Corporation (AMWL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMWL: -98. 3%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AMWL and OPRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMWL is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.